Eyes Wide Open: What I Wish Every Dentist Knew Before Signing a DSO Contract

I spent seven years in DSO operations. I have seen the model from the inside — the good, the bad, and the financially catastrophic. I have friends who are still thriving in DSOs, and I know doctors whose careers have been derailed by them.

The difference almost always comes down to one thing: information asymmetry.

DSOs are a legitimate path. But the contracts are written by the platform, for the platform. They are designed to maximize the DSO’s enterprise value, not the doctor’s take-home pay. This is not malicious — it is business. But when doctors sign these agreements without understanding the downstream financial implications, they walk into traps they cannot escape.

This is not an anti-DSO piece. This is a pro-doctor piece. The goal is to show you how the math actually works, so you can protect yourself.

The Realization Rate Trap: How a $1,500 Crown Becomes $150 in Your Pocket

The offer always sounds reasonable. You will be paid a percentage of production or collections — typically 25–30%. What is not in the offer letter is the realization rate of the office you are placed in.

The DSO, not you, controls which insurance plans the practice accepts. To drive patient volume, many DSOs sign up for every plan available, including low-reimbursement DMOs and capitation plans. This craters the practice’s overall realization rate — the percentage of the full fee schedule that is actually collected.

Here is how it plays out:

1. You perform a crown with a standard fee of $1,500.
2. The patient’s insurance plan, which the DSO contracted with, reimburses $600 for that procedure. The practice’s realization on that crown is 40%.
3. Your employment agreement pays you 25% of collections.
4. Your compensation is 25% of $600 = $150.
5. Some DSOs also deduct lab fees directly from the doctor’s compensation. A crown lab fee typically runs $80–$150. If your contract includes this clause, that $150 becomes $60 or less.

At that point, you have performed a $1,500 procedure, absorbed the cost of the lab case, and walked away with less than 5% of your billed production. You had no say in the insurance contract that cut your fee by 60%. You had no say in the lab the DSO uses or what it charges. You are the last stop before the money runs out.

In theory, a doctor could object to the payer mix before signing. In practice, it almost never happens. A new graduate has no leverage — they have debt, no patient base, and they need the position. An experienced dentist might raise the issue, but the DSO’s answer is typically the same: this is how we operate across all locations, and we do not make exceptions.

The time to understand the realization rate is before you sign — not after you are in.

The Capitation Black Hole: Where Do the True-Up Payments Go?

It gets worse with capitation plans.

Under many DMO/capitation agreements, certain procedures are covered at a rate of $0, with the payment coming later in a quarterly or semi-annual “true-up” payment directly to the contracting entity.

That contracting entity is the DSO, not your practice.

For four years, I watched this happen from the inside. A doctor performs a procedure that the practice management software records as a $0 collection because of the DMO plan. At the end of the quarter, a lump-sum payment of $500 for that procedure arrives. But it does not go to the practice. It goes to the corporate P&L.

The flow:

1. Billed Production: $1,500
2. Practice-Level Collection: $0 (per the DMO contract)
3. Doctor’s Compensation: $0 (because it is based on practice-level collections)
4. Corporate-Level True-Up: $500
5. Who Keeps the $500: The DSO.

This is not a rounding error — it is a structural feature. The money for the work you did exists. It was paid. It just never reaches the financial ledger your compensation is tied to.

Why This Happens: The Recapitalization Incentive

Why would they structure it this way?

The answer is EBITDA. A DSO’s enterprise value is calculated as a multiple of its earnings before interest, taxes, depreciation, and amortization. When private equity acquires a DSO — or when the DSO prepares for its next sale — that multiple is the number that matters. Every dollar of margin improvement at the platform level translates directly into enterprise value at exit.

A DSO generating $10M in EBITDA at a 10x multiple is worth $100M. Push that EBITDA to $12M and the platform is worth $120M — not because the practices got better, but because the math changed.

You are not just an employee. You are the fuel for their next recapitalization. Your realization rate, your lab fees, your capitation true-up — these are not administrative details. They are line items in an EBITDA calculation that determines how much the platform sells for.

The Exit Barrier: Why You Cannot Leave

This brings us to the final piece of the trap: the non-compete.

After a year or two of earning a fraction of what you expected, you decide to leave. But your contract includes a restrictive non-compete — often with a two- or three-year duration and a 20- to 30-mile radius from any of the DSO’s locations, not just the one you worked at.

If you live in the community you serve, you are trapped. You either continue working for a fraction of your value, or you uproot your family and move. The non-compete is not just about protecting trade secrets — it is a retention tool. It makes the cost of leaving so high that most doctors are forced to stay, even after they realize the financial arrangement is untenable.

A Note for Practice Owners: You Just Got Yourself a Boss

Everything above applies to associate doctors. But practice owners considering a DSO sale face a different version of the same problem.

The pitch is compelling. Hand off HR. Hand off recruiting. Hand off payroll, credentialing, and the operational headaches that have been eating your weekends for twenty years. Let the machine handle it while you focus on dentistry. It sounds like freedom.

What it actually is, in most cases, is a trade. You hand off the headaches, and in exchange, you hand off the authority.

You now have a boss. Not in name — the contract will not say that — but in practice. Want to close for a week? You need to clear it. Want to change your fee schedule? That is a corporate decision. Want to bring on a new associate or let a team member go? There is a process, and it runs through someone above you.

And then there are the production targets. When you owned your practice, the financial goals were yours. You set them based on your lifestyle, your debt, your retirement timeline. Inside a DSO, the financial targets are set by the corporation — based on what they need to service their debt, satisfy their investors, and hit their EBITDA projections for the next recapitalization.

None of this means a DSO sale is the wrong move. Sometimes it genuinely makes sense — especially when you are facing a major change: expanding to a second location, navigating a succession, managing a difficult market shift, or reaching a point where the operational burden has become unsustainable. A well-structured DSO relationship can provide capital, infrastructure, and expertise that would take years to build independently.

But the autonomy is gone. That part is not negotiable, and it is not temporary. It is the fundamental nature of the arrangement.

The Bottom Line: Go In With Your Eyes Open

The point of this is not that all DSOs are bad. It is that the financial incentives are not aligned by default. The model is built to reward the platform.

If you are considering a DSO, you must assume that any ambiguity in the contract will be resolved in the DSO’s favor. And you must have your contract reviewed by an attorney who specializes in DSO agreements who can model out the real-world financial implications of these clauses.

Ask the hard questions:

• What is the historical realization rate of the specific office I will be working in?
• How are capitation payments handled, and will they appear on the practice-level P&L?
• Can I see the full fee schedule for the top 10 insurance plans in this office?

If they cannot or will not answer, that is an answer in itself.

---

For the forensic framework behind evaluating DSO offers against independent ownership, see The $2 Million Mistake. If you are within 36 months of a transition, run your EBITDA Leakage Diagnostic to understand what you are actually bringing to the table.